Overview

CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma

Status:
Completed
Trial end date:
2007-02-15
Target enrollment:
Participant gender:
Summary
The purpose of the study is to select the dose regimen of CDC-501 that provides the most promising evidence of efficacy.
Phase:
Phase 2
Details
Lead Sponsor:
Celgene
Celgene Corporation
Treatments:
Lenalidomide